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A B S T R A C T
Purpose: Insulin, in typical use, undergoes multiple changes in temperature; from refrigerator, to room tempera-
ture, to body temperature. Although long-term storage temperature has been well-studied, the short term changes
to insulin are yet to be determined. Insulin detemir (IDet) is a clinically available, slow-acting, synthetic analogue
characterised by the conjugation of a C14 fatty acid. The function of this modification is to cause the insulin to
form multi-hexameric species, thus retarding the pharmacokinetic rate of action. In this investigation, the tem-
perature dependence properties of this synthetic analogue is probed, as well as expiration.
Methods: Dynamic light scattering (DLS) and viscometry were employed to assess the effect of temperature upon
IDet. Mass spectrometry was also used to probe the impact of shelf-life and the presence of certain excipients.
Results: IDet was compared with eight other insulins, including human recombinant, three fast-acting analogues
and two other slow-acting analogues. Of all nine insulins, IDet was the only analogue to show temperature depen-
dent behaviour, between 20 °C and 37 °C, when probed with non-invasive backscatter dynamic light scattering.
Upon further investigation, IDet observed significant changes in size related to temperature, direction of temper-
ature (heated/cooled) and expiration with cross-correlation observed amongst all 4 parameters.
Conclusions: These findings are critical to our understanding of the behaviour of this particular clinically relevant
drug, as it will allow the development of future generations of peptide-based therapies with greater clinical effi-
cacy.
1. Introduction
The therapeutic applicability of a biologically active peptide is con-
tingent on delivering it at its site of action within a suitable timeframe.
Peptide and protein drug delivery is connected with several problems
[29]. Peptides, prone to enzymatic breakdown and poor penetration
through mucosal membranes, must be administered by injection. Addi-
tionally, most peptides have a short half-life within the circulation and
must be progressively released into the bloodstream to have a sustained
effect.
Insulin is a ubiquitous example of a pharmaceutical protein used
in the treatment of diabetes. The main purpose of insulin therapy is
to mirror standard physiological insulin secretion through basal-bolus
administration [13]. In a healthy individual, pancreatic β-cells continu-
ously excrete insulin to maintain plasma glucose levels around 4–6 mM.
In patients diagnosed with diabetes mellitus this mechanism is impaired
and tight glucose control is imperative to reduce the risks of hypo-
glycaemic and hyperglycaemic episodes [12]. However, studies have
shown that normal human insulin (as well as porcine and bovine in-
sulins) and intermediate-acting insulins like NPH have high variability
in terms of pharmacodynamic and pharmacokinetic behaviour in vivo
preceding poor glycaemic control [11,23]. Long acting insulin ana-
logues such as degludec, glargine and detemir have displayed negli
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gible variability, therefore lower risks of nocturnal hypoglycaemia
[7,18], although some studies have disputed this claim [17].
Insulin detemir (IDet) is a long-acting, water-soluble, insulin ana-
logue that differs structurally from human insulin in two respects: the at-
tachment of a 14-carbon fatty acid side chain to LysB29 and the removal
of ThrB30 [10]. The structure of IDet is shown in Fig. 1. These modi-
fications protract insulin activity via self-association at the injection site
and reversible binding to albumin; only the free monomeric fraction of
the molecule can bind to target insulin receptors [10,16,22,28].
In this investigation, we show for the first time that insulin de-
temir is the only analogue that exhibits high temperature dependency.
Shelf-life dependence were also investigated as well as interactions
between these parameters. Although long-term shelf-life/temperature
studies have been performed previously [2,6,21,27], to the authors’
knowledge, this is the first time short-term temperature profiles of in-
sulin have been investigated.
2. Materials and methods
2.1. Insulin
Insulin detemir (IDet), trademarked as Levemir® and manufactured
by Novo Nordisk, was obtained as 3 mL vials, 100U/mL (14.2 mg/mL),
for FlexTouch® pens, as a gift from the Independent Diabetes Trust.
IDet excipients list includes 65.4 μg/mL zinc, 2.06 mg/mL m-cresol,
16.0 mg/mL glycerol, 1.80 mg/mL phenol, 0.89 mg/mL Na2HPO4·2H2O
and 1.17 mg/mL NaCl. HCl and NaOH may have been added by the
manufacturer to adjust pH to 7.4 [20]. These preparations included ex-
pired samples (2013, 2015, 2016, 2017) as well as an in-date batch
(2020). While not in use, all IDet preparations were refrigerated at
~5 °C. All experiments involving expiry of samples were carried out
over a 4 month period in Summer 2018.
Eight other in-date insulins were also screened to assess tempera-
ture dependence, but only for single dose concentrations. These were
Human Recombinant (Novorapid®, Novo Nordisk), Bovine and Porcine
(Hypurin®, Wockhardt), Aspart (Actrapid®, Novo Nordisk), Glulisine
(Apidra®, Sanofi), Lispro (Humalog®, Lilly), Glargine (Lantus®, Sanofi)
and Degludec (Tresiba®, Novo Nordisk).
2.2. Dynamic light scattering
DLS was used as a high-throughput method to monitor the change
in insulin behaviour (indicated by the hydrodynamic radius) at differ-
ent temperatures. All nine insulins were analysed at three temperatures
(20.0, 28.0, 37.0 °C) using a Zetasizer NanoZS (Malvern Panalytical,
Malvern, UK) with a non-invasive back scatter (NIBS) angle of 173°.
The temperature was set to equilibrate for 180 s after every tempera-
ture change and three readings (11 sub-repeats of 10 s correlator detec-
tion) were taken and averaged. Zetasizer software v6.2 was used to ob-
tain light scattering data. The dispersant viscosity at 20.0 °C was used,
and the software was allowed to assume the viscosity at each tempera
Fig. 1. Primary amino acid sequence of insulin Detemir. 21 amino acids in α chain,
29 amino acids in β chain, stabilised by three disulphide bonds (-S-S-, 1 intra, 2 inter) and
conjugated with a C14 fatty acid on the terminal Lysine (K).
ture analysed based on built-in polynomial temperature-viscosity curves.
After it was determined that IDet behaved differently to the other in-
sulins, the different batches were assayed at every 1 °C (20.0–37.0 °C),
both increasing and decreasing temperature trend, and number of repli-
cates increased to 6, with the first measurement deleted to account for
temperature equilibration.
Sealed polystyrene disposable cuvettes (Sartedt AG & Co., Germany)
were used to load the sample into the instrument. A 1 mL syringe with a
Luer-locked 0.8 mm × 40 mm needle (BD Microlance™ 3) was used to
extract the insulin and load into the cuvette. Care was taken to prevent
excessive shear stress.
2.3. Sedimentation velocity
IDet (2020, in-date batch) was analysed using sedimentation veloc-
ity in an analytical ultracentrifuge (Optima XL-I, Beckman Coulter, Palo
Alto, USA). 390 μL of each sample was loaded into centrifuge cells, each
assembled from two sapphire windows, 12 mm aluminium-epoxy resin
2-channel centrepiece, and aluminium housing. 400 μL buffer was in-
jected into the reference side. Each cell was run in a balanced 8-hole
rotor at a speed of 40 000 rpm (127 000g) for 8 h using Rayleigh Inter-
ference optics scanning every 2 min. Data were analysed using SEDFIT
[24].
2.4. Density measurement
The density of IDet samples per expiry date was measured for each
concentration between 20.0 °C (~room temperature) and 37.0 °C
(~body temperature) at 20.0, 25.0, 30.0, 35.0, 37.0 (±0.00005 °C) us-
ing a DMA 5000 oscillating capillary density meter (Anton Paar GmbH,
Graz, Austria).
2.5. Viscometry
IDet solutions were analysed at the same temperatures 20.0, 25.0,
30.0, 35.0, 37.0 (±0.05 °C) using an AMVn rolling ball viscometer (An-
ton Paar GmbH, Graz, Austria) equipped with a 6 d.mm silanised cap-
illary and 5 d.mm steel ball. 14 replicates (4x70°, 4x60°, 6x50°) of 5
serially diluted concentrations were made for each temperature and 3
batches. The specific viscosity ηsp was obtained using the following equa-
tion:
(1)
where η is the dynamic viscosity (taking into account the previously
measured density) and η0 the dynamic viscosity of the solvent. A con-
centration (c) series fitted to the following polynomial model, simplified
to the second order, yielded the intrinsic viscosity [η], and regression
coefficient k values: [4,15]
(2)
2.6. Gas chromatography coupled to mass spectrometry
A Trace 1300 series Gas Chromatograph coupled with single-quadru-
pole mass spectrometer (Thermo-Fisher Scientific, Hemel Hempstead,
UK) was used. Samples were incubated at 37.0 °C for 20 min with
intermittent agitation. Solid phase microextraction (SPME) fibre (50/
30 μm DVB/CAR/PDMS, Supelco, Sigma Aldrich, UK) was used to ex-
tract for 40 min, with a desorption time of 1 min. Splitless mode was
used, and a constant carrier pressure of 18 psi was applied. Separa-
tion was carried out by a ZB-WAX capillary gas chromatography col-
umn (length 30 m, internal diameter 1 mm, 1.00 μm film thickness).
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creased by 6.0 °C every minute up until 250.0 °C, held for 5 min. Full
scan mode was chosen to measure volatile compounds (mass range from
20 to 300 Da). Volatiles were identified by comparison of each mass
spectrum with the spectra from the NIST Mass Spectral Library.
Due to the very high concentrations of phenol and m-cresol in the
insulin formulation, a 1 in 20 dilution was required to achieve accept-
able signal, and not overload the column. Similarly, availability of IDet
preparations limited sample volumes and only batches 2020, 2017, 2016
and 2015 were analysed.
2.7. Statistical analysis
Student t-tests (2-tailed) were performed on the comparative DLS
study, for all nine insulins, using the built-in MS-Excel function (Office
2013). Significance was probed for individual insulins between 20 and
28 °C; 28 and 37 °C; 20 and 37 °C, but not for inter-insulin differences
as this was beyond the scope of the investigation. p ≤ 0.05 and ≤ 0.005
were used to assess level of significance.
A multiple regression general linear model (MANOVA) was per-
formed on the comprehensive IDet DLS dataset using SPSS v23 (IBM).
Controlled variables included temperature, direction (ascending/de-
scending) and expiry. Obvious anomalies (9 points out of 889, 1.0% of
data) were removed before analysis, but the remaining data were repre-
sentative of the entire set. Type IV Sum of Squares was used to take into
account the removal of these data points. A post-hoc Tukey HSD test was
performed to assess groupings between temperatures and expiries.
ANOVA was carried out on intrinsic viscosity data and GC–MS peaks
identified as m-cresol and phenol, and their correlation with ex
piry of sample, using OriginLab 2015. A critical p-value of 0.05 was used
to test for significance.
3. Results
Initial experiments were performed to ascertain the temperature-de-
pendent behaviour of nine clinically available insulins. Dynamic light
scattering (DLS) was used as a fast and reliable method to determine the
hydrodynamic radius (radius of hydrated molecule assuming a perfect
sphere) of each insulin preparation.
3.1. Dynamic light scattering
3.1.1. Initial screening
Fig. 2 exhibits the screening of nine structurally different insulins at
three different temperatures using DLS to measure hydrodynamic size.
Native insulins are presented along the top row (a–c), fast-acting ana-
logues in the middle row (d–f) and slow-acting analogues in the bottom
row (g–i).
Human recombinant insulin (a) presented a hydrodynamic radius of
1.8 nm regardless of the temperature in the measured range. Bovine (b),
Porcine (c), Aspart (d) and Lispro (f) all had radii of 2.3 nm, also in-
dependent of temperature. Glulisine (e) was larger at 2.6 nm. Glargine
(g) and Degludec (i) yielded the smallest radii of the measured insulins,
with values closer to 1.0–1.2 nm.
Depending upon temperature, IDet (h) ranged between 2.3 and
3.1 nm, and from visual analysis appears to significantly decrease in
size with increased temperature (Fig. 2(h)). The significance of this dif-
ference was confirmed using t-tests (p = 0.013, = 0.014, = 0.00056
for 20:28, 28:37, 20:37, respectively). Consequently, addi
Fig. 2. Comparison of 9 different insulins, measured at 3 different temperatures using backscatter dynamic light scattering. (a) Human recombinant; (b) Bovine; (c) Porcine; (d)
Aspart; (e) Glulisine; (f) Lispro; (g) Glargine; (h) Detemir; (i) Degludec. Samples were measured in triplicate and error bars represent the standard deviation. Statistical significance was
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tional experimentation was carried out on IDet to investigate this phe-
nomenon.
3.1.2. Multiple regression analysis of IDet
Results of more detailed analysis of IDet have been presented in Fig.
3, showing hydrodynamic size against temperature, increasing and de-
creasing, with subplots representing the 5 expiries. A clear trend can be
observed in the unexpired (2020) IDet, where there was an inverse rela-
tionship between size (rH) and temperature. The insulin behaviour was
also dependent on the direction from which the temperature equilibrium
was obtained, either from heating (ascending) or cooling (descending).
As the system cooled, the size increased, however not to the original
point obtained when the system was heated. This is most apparent at
20 °C, where the size is either 9 nm or 6 nm, a 1.5 fold difference.
The same trend can be observed for the other expired insulins, but
with 20 °C values decreasing with increased expiry. 37 °C values do not
appear to consistently change with expiration, but descending temper-
atures that start at 37 °C tend to be higher than the same temperature
from ascending only in expired samples.
The statistical analysis is represented graphically in Fig. 4 and sum-
marised in Table 1.
All components and interactions, including second-order (Temper-
ature*Direction*Expiry), yielded statistical significance. This suggests
that the direction of temperature (from heating or cooling), the temper-
ature itself and sample expiration all co-interacted with each other.
3.2. Sedimentation velocity
Sedimentation velocity analysis of IDet, unexpired, showed a com-
plex, heterogeneous system, as shown in Fig. 5. The main component
was a peak at 3.12S, likely to be the hexamer, constituting 66% of
the concentration distribution. Three further peaks at 5.52, 7.10 and
8.99S represented 21%, 7% and 2% of the total concentration respec
tively, and are likely to be multi-oligomers of hexameric IDet. A small
fraction (0.83S, 4%) was also present and is likely to be IDet monomer.
3.3. Intrinsic viscosity
Intrinsic viscosities are plotted in Fig. 6. For the unexpired (2020)
IDet sample, there is a general increasing, but statistically insignificant,
trend with intrinsic viscosity starting at 4.2 mL/g at 20 °C and increas-
ing to 5.6 mL/g at 37 °C (F1,3 = 1.580, p = 0.298). The 1 year expired
(2017) IDet sample shows much greater standard errors in measurement
and an overall decreasing trend (F1,3 = 0.743, p = 0.452). Intrinsic vis-
cosities were, however, approximately the same as unexpired, apart
from two high-error measurements at ~12 mL/g. IDet 2016 (2 year ex-
pired) displayed a similar increasing trend to the unexpired formula-
tion (F1,3 = 3.860, p = 0.144), although intrinsic viscosities, as well as
standard errors, were generally higher, reaching as high as at 7 mL/g.
IDet 2015 exhibited small standard errors and intrinsic viscosities and
were generally higher than the equivalent 2016 samples, as high as
12.5 mL/g at 37 °C, and the same overall increasing trend is still present
(F1,3 = 5.225, p = 0.106). The most expired sample, IDet 2013, exhib-
ited the strongest trend and ANOVA suggests that it was statistically sig-
nificant (F1,3 = 11.80, p = 0.041).
3.4. Gas chromatography coupled to hard-ionisation mass spectrometry
GC–MS analysis yielded two main elution peaks, identified in all
measured samples, at 35.8 min and 37.1 min as phenol and m-cresol, re-
spectively. Identification was performed through hard-ionisation spectra
cross-referenced with the NIST library. Their relative area-under-curve
peak percentages are shown in Fig. 7.
Statistical significance of component percentage (phenol and
m-cresol), measured against expiry, was measured using ANOVA. Both
components indicate a small positive slope (phenol: F1,2 = 0.2196,
p = 0.69. m-cresol: F1,2 = 8.128, p = 0.10).
Fig. 3. Hydrodynamic size of IDet measured using backscatter DLS. Size measured against ascending (black square) or descending (open circle) temperature, across 5 expiries
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Fig. 4. Hydrodynamic radius (z-axis) measured against temperature (x-axis), both ascending and descending (represented by arrows), and by expiry year (y-axis) at native (14.2 mg/mL)
concentration.
Table 1
Summary output of multiple regression general linear model for IDet tempera-
ture dependence (20–37 °C). Size was tested against temperature, direction (ascend-
ing/descending temperature) and expiry (2013, 2015, 2016, 2017, 2020). Only first
and second-order interactions are shown; all main effects were statistically significant
(p < 0.001).
Component F-statistic Significance
Direction*Temperature F17,711 = 4601 p < 0.001
Direction*Expiry F4,711 = 2895 p < 0.001
Temperature*Expiry F68,711 = 57.40 p < 0.001
Direction*Temperature*Expiry F62,711 = 26.51 p < 0.001
Fig. 5. c(s) distribution of sedimentation velocity data for IDet (unexpired).
Other peaks were also present, but only represented ~ 10% of eluted
signal. These included a series of peaks eluting at 11.8–12.2 min all
identified as benzene, representing ~5% of overall signal. This is likely
a degradation product of phenol and m-cresol. Another peak at 13.6 min
was identified as p-/o-xylene representing ~2% of total signal. Again,
this is likely a product of phenol and m-cresol degradation. All other ma-
jor peaks were variations of plausible degradation products (i.e. small,
phenol compounds) of phenol and m-cresol.
4. Discussion
4.1. DLS
Dynamic light scattering was used as a rapid and accurate technique
to screen all nine insulins for temperature dependence. The sizes ob-
tained were consistent with experiments performed under similar condi-
tions, although only at 20.0 °C [1].
Differences in sizes between temperatures were assessed using stu-
dent T-tests. The majority of non-IDet samples were deemed insignifi-
cant (p > 0.05) however statistical significance was observed in insulins
Bovine 28:37 °C (p = 0.05) and Aspart 20:28 °C (p = 0.01). In these in-
stances, the low number of repeats (n = 3) suggests the possibility of
a high type I error (false positive), corroborated by statistical insignifi-
cance between Bovine 20:28 °C, 20:37 °C, and Aspart 28:37 °C, 20:37 °C.
However, the significance found in IDet could not be ignored, consider-
ing p < 0.05 for all 3 pairs, and was evidence enough to continue the
investigation more thoroughly. Upon thorough investigation of IDet, the
same pattern was observed.
The temperature dependence can be explained thermodynamically
that an increase in energy into the system will cause the components
to change from low-energy states (multi-hexameric species [14] into
higher-energy states. In this instance, higher-energy states probably
represent lower-order stoichiometric species such as monomers and
dimers [8]. Thus, an average of these states would appear to reduce
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Fig. 6. Intrinsic viscosity measured for IDet at 5 temperatures and 5 batches. Each intrinsic viscosity was fitted using a second order polynomial of specific viscosity (n = 14) against
5 concentrations (n = 5). Error bars represent standard error of regression. A linear regression, weighted by error bars, represents ANOVA statistical analysis.
Fig. 7. Percentage of peak present after SPME-GC–MS volatile extraction from head-
spaces of IDet preparations. Error bars represent standard deviation based on duplicate
measurements. Line of best fit is a linear regression weighted for error bars.
pacting the size of IDet can also be explained by the rate of this phys-
ical reaction. A slow reaction would mean that, although the physical
temperature of the vial would have equilibrated, the energy states of
IDet assemblies would take more time to achieve the original state. Fur-
thermore, this would also explain the second-order interaction between
direction, temperature and size as an increased temperature would
increase the rate of this reaction. The reaction kinetics of
this stoichiometric change cannot be determined from this experiment
alone but is the subject of further investigation.
Expiration dependence was also significant from MANOVA analysis.
This indicates that a change in structure, past expiry, might impact in-
sulin functionality. Additionally, this change would increase with fur-
ther expiration and this may be a justification for the manufacturer’s
suggested expiration date. The exact mechanism, however, remains un-
clear based on DLS analysis alone.
4.2. Sedimentation velocity
Results from the sedimentation velocity indicated a complex for-
mation of IDet assemblies, ranging from monomer (0.9S, ~ 5900 Da)
up to icositetramer/tetra-hexamer (9.0S, ~140 kDa). However the ma-
jority of material was in the hexameric state (3.1S, ~35.5 kDa), with
multi-hexameric species forming successively. This phenomenon has
been well-documented in acylated insulin analogues [10,25]. However,
ultimately, it is the monomeric form which actively induces the hypogly-
caemic response, and explains the slow-acting nature of this analogue.
4.3. Viscosity
Intrinsic viscosity was also measured to assess both temperature de-
pendence and expiry dependence. The majority of calculated values
were consistent with a globular protein of close-to-spherical confor-
mation [9]. Some values, however, were calculated to be as high as
12.5 mL/g, a value consistent with intrinsic viscosity values of heated
bovine serum albumin reported by Masuelli & Gassmann [19] but were
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to draw conclusions on these values. There were also values that were
observed to be lower than 2.5 mL/g. It is likely that the measurement
of solvent viscosity introduced a degree of error in the calculation, how-
ever the same formulation/value would be used for all subsequent mea-
surements and therefore the trends in intrinsic viscosity against temper-
ature are still valid.
The overall increase in intrinsic viscosity with higher temperature
suggests the insulin assemblies either decrease in overall sphericity or
increase in volume [9]). On first observation, this appears to contradict
the results obtained from DLS, where higher temperature led to a de-
crease in size of all IDet samples. However, it is important to note that
both trends are taken from averages of a complex system of stoichiome-
tries, and that the two methods measure different forms of averages.
Light scattering is heavily biased towards larger particles [26], whereas
the average obtained from viscometry is value closer to what could be
considered a weighted average of species. It is known that IDet forms
a wide variety of species from monomeric to multi-hexameric [1]. It is
possible that increasing the temperature caused a reduction in the num-
ber of multi-hexameric and monomeric species, dissociating or associat-
ing (respectively) into hexameric forms; which would elicit the observed
results. However, without extensive distribution-based methods to probe
this further, it would only be possible to speculate on this behaviour.
4.4. Mass-spectrometry
Phenol and m-cresol are excipients critical to the stability of the in-
sulin hexamer [3], and present in most clinically available insulins; the
exception being Insuman Infusat (Sanofi). This is somewhat surprising
as phenol, and to a lesser extent m-cresol, are carcinogenic compounds,
yet diabetic patients are injecting these formulations multiple times a
day.
The dose of these compounds per injection are relatively low. LD50
for phenol is 140 mg/kg and for m-cresol is 242 mg/kg [5]. With up to
3.5 mg/mL of phenol/m-cresol per vial, vast quantities would need to
be injected to achieve toxicity, however the long-term effects of multiple
injections every day are still not fully understood.
The presence of excipient degradation products in IDet samples, as
discovered with GC–MS, is not surprising, nor is the decrease in phenol
and m-cresol with increased expiration. Although the statistical analysis
suggests that this is not significant, for m-cresol the level of significance
was p = 0.10, which is indicative of an effect even if it did not meet the
0.05 cut-off. Similar to the DLS screening statistical analysis, there may
be a risk of type II error (false negative) based on the small repeat size
(n = 2). Further replicates were not possible due to sample availability.
The potential depletion of these excipients would perhaps explain
the behaviour observed in DLS and intrinsic viscosity measurements
where expiration caused an effect in both. For the MANOVA analysis, in
which interactions between the components were observed, it is likely
that the ability to stabilise the hexamer would have follow-on implica-
tions for the reaction kinetics (temperature dependence, temperature di-
rection dependence).
One of the limitations of using SPME-GC–MS was that the relative
percentages of the two excipients are representative of diluted samples,
as the very high concentrations of phenol and m-cresol are over the lim-
its for SPME. Therefore, their actual concentration may also impact their
partitioning in the gas phase.
4.5. Impact on patient therapy
The use of insulin involves several changes in environmental tem-
perature. Vials of insulin remain between 2 and 8 °C while stored at
pharmacies and ~5 °C in patient refrigerators (assuming, of course, pa
tient adherence to storage instructions). Patients then inject the insulin,
perhaps with a brief warming period (vial rolled between hands), where
the bolus sits as a depot in the sub-cutaneous layer. It can be assumed
that insulin entering the bloodstream reach 37 °C but the temperature
state in-bolus remains uncertain. The equilibrium exchange between sto-
ichiometric forms has been conclusively shown to be impacted by the
temperature and therefore the rate of absorption of monomers into the
bloodstream is reduced.
It is still unclear what mechanism underlies the temperature-depen-
dence functional difference between IDet and the other clinically rele-
vant insulins. However, this is currently under investigation by our re-
search team and will be the topic of future publications. It is critical to
discover this mechanism as temperature dependence is directly linked
to clinical behaviour and patient therapy. With further understanding,
temperature dependence may lead to the development of future genera-
tions of peptide-based therapies with greater clinical efficacy.
5. Conclusion
Nine clinically-available insulins were assessed for their temperature
dependence, but only IDet showed a significant reduction in apparent
size. Upon further investigation, an effect was observed that the tem-
perature history/direction of heating/cooling impacts the apparent size,
which was confirmed with viscometry (measuring intrinsic viscosity.
It was posited that the temperature impacted the stoichiometric ratio,
measured through sedimentation velocity, with the difference in temper-
ature history suggesting a slow rate of reaction.
Furthermore, expiration was also probed for its effect on size and ex-
cipient concentration for IDet compared to in-date preparation. Expired
samples (1–5 years out of date) showed a smaller size at 20 °C (ascend-
ing) and a proportional disparity between values at 37 °C (descending).
Although an explanation for IDet’s behaviour was made, the reason
the same phenomenon was not observed in the other eight insulins is
still unclear and is the focus of further investigation.
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